AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31577372 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual abstracts
Number of subjects: 41
Study 31577372 — intervention group
Group type: COMPARATOR
Intervention: Standard tweets
Number of subjects: 41
Study 30291068 — intervention group
Group type: EXPERIMENTAL
Intervention: PilAm Go4Health intervention (3 months)
Number of subjects: 45
Study 30291068 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (received PilAm Go4Health in phase 2)
Number of subjects: 45
Study 25763524 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidcombe Program without instruction to parents to use the verbal contingency request for self-correction
Number of subjects: 34
Study 25763524 — intervention group
Group type: COMPARATOR
Intervention: Standard Lidcombe Program
Number of subjects: 34
Study 23911864 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+aPDT
Number of subjects: 15
Study 20215488 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly gym-based exercise programme
Number of subjects: 106
Study 20215488 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly gym-based exercise programme
Number of subjects: 106
Study 20215488 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 106
Study 19860300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 115
Study 16399292 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium infusion
Number of subjects: 280
Study 16399292 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose 5%)
Number of subjects: 280
Study 15250255 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (3 g/d)
Number of subjects: 40
Study 15250255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11236069 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg three times a day
Number of subjects: 30
Study 11236069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9315414 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinyl estradiol and 2.00 mg dienogest
Number of subjects: 40
Study 9315414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8363115 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% diphenhydramine
Number of subjects: 10
Study 8363115 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine
Number of subjects: 10
Study 3527109 — intervention group
Group type: EXPERIMENTAL
Intervention: Transderm scopolamine disc
Number of subjects: 5
Study 3527109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 29099421 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily with propranolol
Number of subjects: 23
Study 29099421 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 23
Study 27572290 — intervention group
Group type: EXPERIMENTAL
Intervention: Optia
Number of subjects: 154
Study 27572290 — intervention group
Group type: COMPARATOR
Intervention: Spectra-Auto
Number of subjects: 154
Study 26259978 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injection of insulin aspart
Number of subjects: 20
Study 26259978 — intervention group
Group type: COMPARATOR
Intervention: Conventional pen injection of insulin aspart
Number of subjects: 20
Study 24050578 — intervention group
Group type: EXPERIMENTAL
Intervention: 400mg caper fruit extract three times a day for two months
Number of subjects: 54
Study 24050578 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules three times a day for two months
Number of subjects: 54
Study 21878082 — intervention group
Group type: EXPERIMENTAL
Intervention: fixed combination amlodipine/valsartan
Number of subjects: 86
Study 21878082 — intervention group
Group type: COMPARATOR
Intervention: traditional therapy
Number of subjects: 86
Study 19407662 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg b.i.d.)
Number of subjects: 178
Study 19407662 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole (40 mg b.i.d.)
Number of subjects: 178
Study 19407662 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 extensive metabolizers (EMs)
Number of subjects: 178
Study 19407662 — intervention group
Group type: COMPARATOR
Intervention: CYP2C19 poor metabolizers (PMs)
Number of subjects: 178
Study 17028853 — intervention group
Group type: COMPARATOR
Intervention: MRI finding of post‐traumatic neuroma
Number of subjects: 31
Study 17028853 — intervention group
Group type: COMPARATOR
Intervention: MRI finding of pseudomeningocele
Number of subjects: 31
Study 14871464 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients
Number of subjects: 38
Study 14871464 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study 11728960 — intervention group
Group type: EXPERIMENTAL
Intervention: sFas levels in patients with CAD (n = 64)
Number of subjects: 107
Study 11728960 — intervention group
Group type: COMPARATOR
Intervention: sFas levels in patients without CAD (n = 43)
Number of subjects: 107
Study 11728960 — intervention group
Group type: EXPERIMENTAL
Intervention: sFas levels
Number of subjects: 107
Study 11728960 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of one quintile in plasma concentration of sFas
Number of subjects: 107
Study 11728960 — intervention group
Group type: EXPERIMENTAL
Intervention: Models incorporating sFas
Number of subjects: 107
Study 9210707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined immunotherapy with IL-2 and LAK cells after chemotherapy or radiotherapy (Group A)
Number of subjects: 174
Study 9210707 — intervention group
Group type: COMPARATOR
Intervention: Control standard therapy (Group B)
Number of subjects: 174
Study 9210707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined immunotherapy (Group A)
Number of subjects: 174
Study 7712675 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (50 micrograms/puff)
Number of subjects: 25
Study 7712675 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (100 micrograms/puff)
Number of subjects: 25
Study 7712675 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide (250 micrograms/puff)
Number of subjects: 25
Study 7712675 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide (one puff four times a day, increased after 1 week and 2 weeks)
Number of subjects: 25
Study 7712675 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (two puffs four times a day, increased after 1 week and 2 weeks)
Number of subjects: 25
Study 2655683 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathic preparation
Number of subjects: 478
Study 2655683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study 198838 — intervention group
Group type: COMPARATOR
Intervention: Stable methadone intake
Number of subjects: 0
Study 198838 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual withdrawal
Number of subjects: 0
Study 198838 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute withdrawal
Number of subjects: 0
Study 30396098 — intervention group
Group type: EXPERIMENTAL
Intervention: BASICS+EC
Number of subjects: 180
Study 30396098 — intervention group
Group type: EXPERIMENTAL
Intervention: BASICS
Number of subjects: 180
Study 30396098 — intervention group
Group type: COMPARATOR
Intervention: Information
Number of subjects: 180
Study 26780403 — intervention group
Group type: EXPERIMENTAL
Intervention: ResMed Mirage FX® (MFX)
Number of subjects: 195
Study 26780403 — intervention group
Group type: COMPARATOR
Intervention: Control mask (Fisher & Paykel Zest®, HC407® or Philips EasyLife®)
Number of subjects: 195
Study 25641242 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 20
Study 25641242 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 20
Study 25641242 — intervention group
Group type: COMPARATOR
Intervention: Control (Normotensive infants not receiving vasopressor support)
Number of subjects: 20
Study 25899533 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 0
Study 25899533 — intervention group
Group type: COMPARATOR
Intervention: Sham RIPC (Control)
Number of subjects: 0
Study 23306310 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V Leiden (FVL) mutation
Number of subjects: 753
Study 23306310 — intervention group
Group type: EXPERIMENTAL
Intervention: G20210A prothrombin (FII) mutation
Number of subjects: 753
Study 23306310 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex and isolated DVT
Number of subjects: 753
Study 23306310 — intervention group
Group type: EXPERIMENTAL
Intervention: FVL and FII mutations
Number of subjects: 753
Study 21415581 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (DSE) at peak infusion (40 μg/kg/min)
Number of subjects: 71
Study 21415581 — intervention group
Group type: COMPARATOR
Intervention: Cirrhosis group
Number of subjects: 71
Study 18721181 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive airway clearance (AC) strategy, performed twice daily
Number of subjects: 36
Study 18721181 — intervention group
Group type: COMPARATOR
Intervention: Reactive airway clearance (AC) strategy, performed only in presence of chest infection
Number of subjects: 36
Study 16669959 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (aminosalicylates and weekly tapered corticosteroids)
Number of subjects: 34
Study 16669959 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin therapy (standard therapy plus enoxaparin 100 Anti‐Xa IU/kg/day subcutaneously)
Number of subjects: 34
Study 12505947 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming with one cotton blanket
Number of subjects: 300
Study 12505947 — intervention group
Group type: COMPARATOR
Intervention: Reflective-blanket with one cotton blanket
Number of subjects: 300
Study 12505947 — intervention group
Group type: COMPARATOR
Intervention: Two-cotton-blanket group
Number of subjects: 300
Study 11728290 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (16 mg once daily, titrated to 32 mg as needed, with hydrochlorothiazide 12.5 mg as needed)
Number of subjects: 304
Study 11728290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 9414372 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent lime-yellow test garment
Number of subjects: 14
Study 9414372 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent orange test garment
Number of subjects: 14
Study 9414372 — intervention group
Group type: EXPERIMENTAL
Intervention: White test garment
Number of subjects: 14
Study 8126257 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 mcg/day
Number of subjects: 9
Study 8126257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8126257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 2400 mg/day
Number of subjects: 9
Study 3110681 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine added to dialysis fluid at a final concentration of 100 mumol/l
Number of subjects: 21
Study 29618011 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (DZX)
Number of subjects: 0
Study 29618011 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study 28589493 — intervention group
Group type: EXPERIMENTAL
Intervention: Omarigliptin 25 mg once weekly
Number of subjects: 0
Study 28589493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28589493 — intervention group
Group type: EXPERIMENTAL
Intervention: Omarigliptin/omarigliptin
Number of subjects: 0
Study 28589493 — intervention group
Group type: COMPARATOR
Intervention: Placebo/omarigliptin
Number of subjects: 0
Study 24445038 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin intervention
Number of subjects: 0
Study 24445038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23558890 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg daily
Number of subjects: 519
Study 23558890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study 20587129 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS treatment (n=14)
Number of subjects: 28
Study 20587129 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS treatment (n=14)
Number of subjects: 28
Study 18156403 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene at a dose of 15 mg/d for 6 months
Number of subjects: 40
Study 18156403 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 40
Study 18156403 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene and Placebo
Number of subjects: 40
Study 17094774 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol + ascorbic acid
Number of subjects: 352
Study 17094774 — intervention group
Group type: COMPARATOR
Intervention: Sodium phosphate solution
Number of subjects: 352
Study 12554889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrite and nitrate levels in induced sputum
Number of subjects: 30
Study 12554889 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroxynitrite inhibitory activity in induced sputum
Number of subjects: 30
Study 12554889 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between nitrite/nitrate levels and peroxynitrite inhibitory activity
Number of subjects: 30
Study 12554889 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between peroxynitrite inhibitory activity and FEV(1) % predicted
Number of subjects: 30
Study 12554889 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between peroxynitrite inhibitory activity and FEV(1)/FVC
Number of subjects: 30
Study 12554889 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between peroxynitrite inhibitory activity and carbon monoxide transfer factor (TLCO)
Number of subjects: 30
Study 12554889 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between peroxynitrite inhibitory activity and percentage of neutrophils
Number of subjects: 30
Study 12554889 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between peroxynitrite inhibitory activity and IL‐8 levels
Number of subjects: 30
Study 10824502 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Number of subjects: 0
Study 10824502 — intervention group
Group type: COMPARATOR
Intervention: Motor skills training (Control)
Number of subjects: 0
Study 8648368 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin, vincristine, cyclophosphamide, and fluorouracil (AVCF)
Number of subjects: 249
Study 8648368 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 249
Study 7956768 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 44
Study 7956768 — intervention group
Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 44
Study 7956768 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography
Number of subjects: 44
Study 3426370 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (Imodium) at an average dose of 20 to 25 drops/kg/24 h (0.16 to 0.20 mg/kg/24 h), given every 8 hours for at least 48 hours.
Number of subjects: 63
Study 3426370 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 63
Study 3426370 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (Imodium)
Number of subjects: 63
Study 29998815 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative analgesics (paracetamol and ibuprofen)
Number of subjects: 45
Study 29998815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 26983924 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 43
Study 26983924 — intervention group
Group type: COMPARATOR
Intervention: Intensive lifestyle and medical intervention (ILMI)
Number of subjects: 43
Study 24048485 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 1279
Study 24048485 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 1279
Study 22542118 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for mild gestational diabetes mellitus
Number of subjects: 932
Study 22542118 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 932
Study 20565484 — intervention group
Group type: EXPERIMENTAL
Intervention: Airsonett Airshower (AA) treatment with allergen-free air during night sleep
Number of subjects: 0
Study 20565484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18388881 — intervention group
Group type: EXPERIMENTAL
Intervention: tesaglitazar
Number of subjects: 0
Study 16185038 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Orthopedic Surgery (CAOS)
Number of subjects: 16
Study 16185038 — intervention group
Group type: COMPARATOR
Intervention: Image Intensifier Control
Number of subjects: 16
Study 12641688 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.1 mg.kg(‐1))
Number of subjects: 60
Study 12641688 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg.kg(‐1))
Number of subjects: 60
Study 12641688 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (2 mg.kg(‐1))
Number of subjects: 60
Study 10993491 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption plasmapheresis (IA)
Number of subjects: 5
Study 10993491 — intervention group
Group type: EXPERIMENTAL
Intervention: Double filtration plasmapheresis (DF)
Number of subjects: 5
Study 8869675 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA), size 3 or 4
Number of subjects: 11
Study 8869675 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT) 8.0 mm
Number of subjects: 11
Study 2005049 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child interaction training (experimental group)
Number of subjects: 0
Study 2005049 — intervention group
Group type: COMPARATOR
Intervention: Minimal treatment (control group)
Number of subjects: 0
Study 6193666 — intervention group
Group type: EXPERIMENTAL
Intervention: Admixture group: 20 ml dextran 1, 15% (Promiten) mixed with 500 ml dextran 70 (Macrodex) or dextran 40 (Rheomacrodex)
Number of subjects: 12060
Study 6193666 — intervention group
Group type: COMPARATOR
Intervention: Preinjection group: 20 ml dextran 1, 15% administered before the infusion of dextran 70 or 40
Number of subjects: 12060
Study 30854693 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial approach with radiographic assistance
Number of subjects: 98
Study 30854693 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsolateral approach with radiographic assistance
Number of subjects: 98
Study 30854693 — intervention group
Group type: COMPARATOR
Intervention: Medial approach without radiographic assistance
Number of subjects: 98
Study 30854693 — intervention group
Group type: COMPARATOR
Intervention: Dorsolateral approach without radiographic assistance
Number of subjects: 98
Study 30572932 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocacy campaigns to reduce tobacco consumption through behavioral nudges via randomized controlled trials (RCTs)
Number of subjects: 985
Study 30572932 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide readings for short term smoking measurement
Number of subjects: 985
Study 30572932 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1 and PEF values
Number of subjects: 985
Study 27553442 — intervention group
Group type: EXPERIMENTAL
Intervention: PCFNB (bolus infusion of 3 ml with a lockout time of 30 min and no basal infusion)
Number of subjects: 56
Study 27553442 — intervention group
Group type: COMPARATOR
Intervention: cFNB (basal infusion of 6 ml/h using a dummy bolus button)
Number of subjects: 56
Study 27553442 — intervention group
Group type: EXPERIMENTAL
Intervention: PCFNB
Number of subjects: 56
Study 27553442 — intervention group
Group type: COMPARATOR
Intervention: cFNB
Number of subjects: 56
Study 27553442 — intervention group
Group type: EXPERIMENTAL
Intervention: PCFNB and cFNB
Number of subjects: 56
Study 24132707 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron film-coated tablets (test product)
Number of subjects: 0
Study 24132707 — intervention group
Group type: COMPARATOR
Intervention: Zofran (reference product)
Number of subjects: 0
Study 22263710 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (MMT) initiated prior to release from incarceration
Number of subjects: 0
Study 19021604 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative dose of ciprofloxacin (2 tablets of 500 mg each, 2 hours before biopsy)
Number of subjects: 288
Study 19021604 — intervention group
Group type: COMPARATOR
Intervention: 3-day course of ciprofloxacin
Number of subjects: 288
Study 17618422 — intervention group
Group type: EXPERIMENTAL
Intervention: New remission criteria
Number of subjects: 1708
Study 17618422 — intervention group
Group type: EXPERIMENTAL
Intervention: New remission criteria with item threshold 'at best very mild symptoms'
Number of subjects: 1708
Study 17618422 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotic symptoms component
Number of subjects: 1708
Study 17618422 — intervention group
Group type: EXPERIMENTAL
Intervention: CGI severity score mild or better
Number of subjects: 1708
Study 17618422 — intervention group
Group type: COMPARATOR
Intervention: At least 50% BPRS reduction
Number of subjects: 1708
Study 17618422 — intervention group
Group type: COMPARATOR
Intervention: CGI improvement score of at least 'much better'
Number of subjects: 1708
Study 14996607 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthine oxidase inhibition in smokers
Number of subjects: 24
Study 14996607 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 24
Study 14996607 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 24
Study 12537268 — intervention group
Group type: EXPERIMENTAL
Intervention: Written standardized information and non-standardized verbal information (intervention group)
Number of subjects: 123
Study 12537268 — intervention group
Group type: COMPARATOR
Intervention: Non-standardized verbal information (control group)
Number of subjects: 123
Study 9814476 — intervention group
Group type: EXPERIMENTAL
Intervention: ERalpha and ERbeta mRNA expression in prolactinomas (n = 14)
Number of subjects: 77
Study 9814476 — intervention group
Group type: EXPERIMENTAL
Intervention: ERbeta mRNA expression in tumors expressing PRL and GH (n = 6)
Number of subjects: 77